Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Non-GAAP R&D expenses as % of total revenues by Year
Non-GAAP R&D expenses as % of total revenues (%) (%)
Gilead Sciences Non-GAAP R&D expenses as % of total revenues: 19.3% in FY2025, down 0.6 pts from a year earlier.
Where the FY2025 figure comes from
“|| Research and development expenses as a % of revenues | 19.7 | % | 21.3 | % | -155 bps | 19.3 | % | 19.9 | % | -62 bps”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Reported in Form 8-K Non-GAAP Financial Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP R&D expenses as % of total revenues (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19.3% | -0.6 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 19.9% | -1.2 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | 21.1% | +2.9 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 18.2% | +1.9 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 16.3% | -3.4 pts | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 19.7% | – | Form 8-K (exhibit991earningspressrel.htm, filed 2022-02-01) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Non-GAAP R&D expenses as % of total revenues (%), annual FY2020–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd-nongaap-pct-rev
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.